# DESCRIPTION

## FIELD OF INVENTION

- define novel vaccine consortium

## BACKGROUND AND PRIOR ART OF THE INVENTION

- summarize enteric fever problem
- limitations of current vaccines

## OBJECTIVES OF THE INVENTION

- list objectives of invention

## DETAILED DESCRIPTION OF THE INVENTION

- describe novel formulation of isolated outer membrane vesicles from two thyphoidal Salmonella strains
- detail immunogenicity and protective efficacy studies in adult mice
- highlight advantages of the formulation over conventional methods

### Bacterial Strains and Culture Conditions

- describe preparation of OMV antigens from S. typhi C-6953 and S. paratyphi A C-6915 strains

### Preparation of OMVs

- outline steps for preparing OMVs from two Salmonella enterica strains

### Negative Staining of OMVs and OMV-Secreting Bacteria

- describe negative staining procedure for OMVs and OMV-secreting bacteria

### Animals

- describe animal model used for immunization and challenge studies

### Collection of Serum and Stool

- outline procedures for collecting serum and stool samples from immunized mice

### SDS-PAGE and Immunoblot

- describe SDS-PAGE and immunoblot analysis of OMV proteins

### Dot Blot Assay.

- outline dot blot analysis procedure for detecting LPS-specific antibodies

### ELISA

- describe ELISA procedure for measuring immunoglobulins against OMVs
- detail ELISA results for IgG, IgG1, IgG2a, IgG3, IgA, and IgM responses

### Ex Vivo Studies on Isolated Dendritic Cells

- describe dendritic cell culture and treatment with bivalent OMV
- outline measurement of cytokines IFN-γ, IL-4, IL-12p70, IL-1β, and IL-23
- describe splenocyte re-stimulation assay
- outline measurement of cytokines IFN-γ, IL-6, and IL-17
- detail results of splenocyte re-stimulation assay
- describe motility assay
- outline results of motility assay
- describe immunization and challenge studies
- detail results of immunization and challenge studies

## The Non-Limiting Advantages are Given Below:

- list advantages of consortium

